Chimeric Therapeutics announces breakthrough AML response with CHM CORE-NK in Phase 1B trial

Chimeric Therapeutics has reported a significant milestone in its ongoing clinical trials, wherein a patient diagnosed with Acute Myelogenous Leukemia (AML) has exhibited a complete ... Read More